Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4508 results about "Polynucleotide" patented technology

A polynucleotide molecule is a biopolymer composed of 13 or more nucleotide monomers covalently bonded in a chain. DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) are examples of polynucleotides with distinct biological function. The prefix poly comes from the ancient Greek πολυς (polys, many). DNA consists of two chains of polynucleotides, with each chain in the form of a helical spiral.

Compositions and methods for modulating circulating factors

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.
Owner:FLAGSHIP ENTREPRENEURSHIP & INNOVATION NO 7 CO LTD

Polyelement polyA polynucleotide for improving mRNA stability and protein expression and application thereof

The invention provides a multielement polyA polynucleotide for improving mRNA (messenger ribonucleic acid) stability and protein expression and application of the multielement polyA polynucleotide. The invention firstly provides a polynucleotide, the polynucleotide comprises more than two sections of polyA sequence fragments, the adjacent polyA sequence fragments are connected through Linkers, each polyA sequence fragment is composed of one or more continuous A, and each Linker is composed of C and / or G. The polynucleotide provided by the invention can improve mRNA stability and protein expression, and compared with a traditional unit poly-A sequence, the polynucleotide provided by the invention can greatly reduce the recombination rate of fermentation in escherichia coli so as to more easily optimize and amplify the process, and can be better applied to plasmid fermentation related to transcription template preparation in mRNA vaccine or drug production.
Owner:SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD +1

Compositions and methods for sample analysis

Provided herein are systems and methods for analyzing biomolecules (e.g., nucleic acid molecules, proteins). A method of nucleic acid analysis can comprise: (a) providing a sample comprising a cell comprising a target polynucleotide comprising a first exon segment and a second exon segment, wherein the first exon segment and the second exon segment flank opposite ends of a splice junction site of the target polynucleotide. The method can further comprise (b) contacting the cell with: (i) a first probe, wherein the first probe hybridizes to a first target sequence of the first exon segment, and (ii) a second probe, wherein the second probe hybridizes to a second target sequence of the second exon segment. The method can further comprise (c) linking the first probe and the second probe together, thereby generating a probe-linked nucleic acid molecule comprising the first probe and the second probe. The method can further comprise (d) identifying a sequence of the probe-linked nucleic acid molecule or derivative thereof, thereby locating the splice junction site of the target polynucleotide.
Owner:10X GENOMICS INC

Verticillium dahliae virulence gene, verticillium dahliae virulence protein and application

The invention relates to the technical field of biology, in particular to a verticillium dahliae virulence gene, a verticillium dahliae virulence protein and application. The invention discloses a verticillium dahliae virulence gene VdPHO23like. The verticillium dahliae virulence gene VdPHO23like comprises a polynucleotide sequence for coding an amino acid sequence of SEQ ID NO: 3. According to the invention, expression of the gene is inhibited in a targeted manner through an RNA interference mediated gene silencing technology so as to weaken virulence of pathogenic bacteria, and an efficient, specific and environment-friendly comprehensive prevention and control strategy is provided for verticillium wilt of crops such as cotton.
Owner:BEIJING ZHONGKE KESHIBO BIOTECHNOLOGY CO LTD

FcRn / HSA binding molecules and methods of use

Provided herein are binding molecules comprising a human neonatal Fc receptor (FcRn) binding molecule and at least one antigen-binding domain linked to the FcRn binding molecule. Polynucleotides, vectors, host cells, and methods of production are also provided herein. Methods of treating an antibody-mediated disorder with an FcRn / antigen-binding molecule are further provided.
Owner:ARGENX BVBA(BE)

Improved prime editors and methods of use

The present disclosure provides compositions and methods for prime editing with improved editing efficiency and / or reduced indel formation with modified prime editors and prime editor fusion proteins. The disclosure further provides, vectors, cells, and kits comprising the compositions and polynucleotides of the disclosure.
Owner:THE BROAD INST INC

Compositions for treating cancer with KRAS mutations and uses thereof

The present application provides guide RNAs and genome-editing complexes or nanoparticles that are useful for specifically targeting a mutated KRAS. Exemplary genome-editing complexes or nanoparticles comprise cell-penetrating peptides, and optionally a DNA nuclease (such as Cas9) or a polynucleotide encoding the DNA nuclease.
Owner:AADIGEN LLC

FtACA13 gene derived from tartary buckwheat and expression vector and application of FtACA13 gene

ActiveCN119685356AHydrolasesFermentationPolygonum fagopyrumFagopyrum tataricum
The invention discloses an FtACA13 gene derived from tartary buckwheat as well as an expression vector and application of the FtACA13 gene. According to the invention, the FtACA13 gene is separated from tartary buckwheat; the polynucleotide sequence of the FACA13 gene is as shown in SEQ ID NO.1, and the amino acid sequence of the encoded protein of the FACA13 gene is as shown in SEQ ID NO.2. The FtACA13 gene is genetically transformed into buckwheat to obtain transgenic buckwheat hairy roots with the overexpressed FtACA13 gene, compared with hairy roots of a control group, the growth vigor and fresh weight of the fagopyrum tataricum hairy roots with the overexpressed FtACA13 gene under salt stress are increased, Na < + > accumulation in a plant body is remarkably low, it is proved that the FtACA13 gene can regulate and control the salt stress resistance of the plant, and the salt stress resistance of the fagopyrum tataricum hairy roots is improved. The invention has application prospects in the aspects of cultivating or breeding salt stress resistant plant varieties and the like.
Owner:INSTITUTE OF CROP SCIENCE CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Methods and systems for processing polynucleotides

The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing and analyte characterization. Such polynucleotide processing may be useful for a variety of applications, including analyte characterization by polynucleotide sequencing. The compositions, methods, systems, and devices disclosed herein generally describe barcoded oligonucleotides, which can be bound to a bead, such as a gel bead, useful for characterizing one or more analytes including, for example, protein (e.g., cell surface or intracellular proteins), genomic DNA, and RNA (e.g., mRNA or CRISPR guide RNAs). Also described herein, are barcoded labelling agents and oligonucleotide molecules useful for “tagging” analytes for characterization.
Owner:10X GENOMICS INC

Nanopore sequencing

Systems and methods for sequencing polynucleotides using nanopores are disclosed. In some embodiments, a polynucleotide including a single-stranded region and a double-stranded region, in which the single-stranded region is disposed through a nanopore. The polynucleotide can be moved relative to the nanopore by electric forces while one or more structural locks keep the polynucleotide close to the nanopore. A characteristic signal based on nanopore ionic current blockade and associated with the regions of the polynucleotide at or near the nanopore recognition zone is measured and used to infer the nucleobase sequence of the polynucleotide. In some examples, the double-stranded region is extended by a polymerase, and the polymerase is removed from the polynucleotide. In some examples, signals measured under different applied voltages provide nonredundant information regarding the polynucleotide sequence.
Owner:ILLUMINA INC

Anti-cmet antibodies

The present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to human cMET. The disclosure also provides polynucleotides encoding the antibodies or antigen binding fragments thereof, vectors comprising the polynucleotides, host cells comprising the vectors, methods of generating the antibodies, and compositions comprising the antibodies.
Owner:BEIGENE (SHANGHAI) CO LTD

Anti-transferrin receptor antibodies and uses thereof cross reference to related applications

The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of use for delivery of cargo to brain tissue. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.
Owner:BIOGEN MA INC

Fluorinase variant

PCT designated stageWO2025170533A1TransferasesFermentationA-siteAdenosine
There is provided a fluorinase variant thereof having at least 70% sequence identity to a sequence MSDLGX6TDDSVAQCKGLMLSICPX24VX26IX28DX30CHX33MTPX37DVVEGARYIVDLPR X52FPEGTVFATTTYPATGTX70X71RSVAX76RX78KX80AALGGARGQX90AGSGX95GX97E RAEGX103YIYIAPNNGLLTX116VIEEHGYX124EAYEVSX131TX133VIPX137X138PEPTFYSR EMVAIPSAHLAAGFPLX163X164VGRX168LX170DX172EIVRFEX179X180KX182X183X184VX186G X188X189LX191GX193X194X195X196X197DHPFGNX204WTNX208HRTDLEKAGIX219YX221TX223X 224KX226VX228DGVLX233FX235LPLX239PTFADAX246X247X248GX250PVX253YX255NSRGYLX2 62X263ARNAAX269LAYPYNLX277AGX280SVX283VTX286A (SEQ ID NO: 1), wherein X is a natural amino acid, and wherein the variant comprises one or more mutations at a site selected from the group consisting of an ion-egress site, a S-Adenosyl-L-Methionine (SAM) binding site, an ion-binding site (IBS), and a conserved site. Also disclosed are polynucleotides encoding the variants, vectors comprising the polynucleotides encoding the variants, and host cells comprising the vectors thereof. Also disclosed are Methods for producing the variants, methods of catalyzing the fluorination of a compound, uses of the fluorinase variants, and methods of treatment using the fluorinase variants thereof.
Owner:AGENCY FOR SCI TECH & RES

Multiple priming for on-support nucleic acid amplification

The present disclosure provides compositions, apparatus and methods for generating a plurality of concatemer template molecules immobilized on a support for conducting massively parallel sequencing runs. In some embodiments, the concatemer template molecules can be generated by conducting rolling circle amplification reactions on a support comprising a mixture of immobilized capture and pinning primers. The rolling circle amplification reaction comprises a plurality of circularized polynucleotide molecules and soluble amplification primers which generates concatemer template molecules that collapse to form compact DNA nanoballs that are stably immobilized to a support.
Owner:ELEMENT BIOSCIENCES INC

Cancer vaccine

Provided herein are systems, compositions, and methods for generating immunogenic peptides or epitopes from tumor associated antigens (e.g., in vivo or ex vivo). Polynucleotides (e.g., genes) encoding the tumor associated antigens may be edited at selected target sites by nucleobase editors comprising a catalytically-inactive Cas9 and a cytosine deaminase, leading to the expression of heteroclitic or cryptic peptides that are more immunogenic than the native peptide derived from the tumor associated antigens. The heteroclitic or cryptic peptide elicit strong tumor-specific immune response (e.g., T-cell response or B-cell response), which inhibits tumor growth and metastasis.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Analysis of a polynucleotide via a nanopore system

ActiveUS12351867B2Microbiological testing/measurementNucleotideRestriction site
A target polynucleotide is expanded. In respect of each nucleotide in the target polynucleotide, the target polynucleotide comprises clock nucleotides and at least one signal nucleotide in a predetermined order. The clock nucleotides have a predetermined sequence common to each nucleotide in the target polynucleotide. The at least one signal nucleotide is characteristic of the identity of the respective nucleotide in the target polynucleotide. During translocation of the expanded polynucleotide through a nanopore, electrical measurements dependent on the polynucleotide within the pore are made, to derive an analysis signal. Clock signals derived from the clock nucleotides are identified. Relative to the positions of the identified clock signals, nucleotide signals derived from the least one signal nucleotide are derived to analyse the target polynucleotide. The predetermined sequence of the clock nucleotides comprises a restriction site for a restriction enzyme and at least one further nucleotide that extends the predetermined sequence.
Owner:OXFORD NANOPORE TECH LTD

Base editing methods and compositions for treating triplet repeat disorders

The present disclosure provides compositions and methods useful in the treatment of trinucleotide repeat disorders, including Huntington's disease and Friedreich's ataxia. The present disclosure also provides gRNAs designed to target the HTT or FXN genes. Complexes comprising a base editor and any of the gRNAs disclosed herein are also provided by the present disclosure. The present disclosure further provides polynucleotides, vectors, cells, compositions, and kits. Methods of treating Huntington's disease and Friedreich's ataxia are also provided herein.
Owner:THE BROAD INST INC

Genetic elements to increase recombinant AAV production

PCT designated stage expiredWO2025054007A9VectorsVirus peptidesGenetic elementPolynucleotide
Polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods for expressing AAV Rep and Cap proteins are provided. In certain aspects, these polynucleotides, cells, and methods may produce higher levels of one or both of Rep and Cap transcripts. In some aspects, these polynucleotides, cells, and methods may produce higher levels of one or both of Rep and Cap proteins. In various aspects, these polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods use one or more heterologous polyA sequences with one or both of the Rep and Cap coding sequences. In numerous aspects, these polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods may use one or more enhancers to increase expression of Rep proteins, where such enhancers can be transcriptional enhancers, translational enhancers, or combinations thereof. In certain aspects, these polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods may be used to produce recombinant AAV (rAAV).
Owner:SHAPE THERAPEUTICS INC +2

Multisubunit RSV, HMPV and HPIV vaccines and therapeutics

PCT designated stageWO2026003578A1SsRNA viruses negative-senseAntibody mimetics/scaffoldsMetapneumovirusHuman Parainfluenza Virus
The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a respiratory syncytial virus, a metapneumovirus, a human parainfluenza virus, or a combination thereof. The multisubunit nucleic acid encodes a multisubunit peptide.
Owner:POPVAX PTE LTD

Methods and systems for improved nucleic acid delivery via ultrasound

PCT designated stage expiredWO2025101509A1SonopheresisOrganic active ingredientsSonoporationPolynucleotide
Provided are methods, compositions, and kits for improving a delivery of a nucleic acid to a cell in an organ of a subject. Such methods, compositions, and kits may include a sonoactive agent and a nucleic acid comprising a cargo polynucleotide and a nuclear localization element and / or an innate immune response avoidance moiety, which may be an aptamer. Delivery may involve sonoporation.
Owner:SONOTHERA INC

Engineered mucosal-associated invariant t (MAIT) cells and methods of making and using thereof

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.
Owner:RGT UNIV OF CALIFORNIA

Polymerase-conjugate binding stabilization

The present disclosure relates in some aspects to methods, systems, and kits for sequencing a template nucleic acid molecule, where the methods comprise: (i) contacting a priming strand bound to the template nucleic acid molecule with a first plurality of nucleotide molecules and a polymerase coupled to a heterologous polynucleotide-binding moiety to form a complex comprising a 3′ terminus of the priming strand, the template nucleic acid molecule, the polymerase, and a nucleotide molecule of the first plurality of nucleotide molecules, wherein the polynucleotide-binding moiety enhances stability of the complex, and wherein the priming strand comprises a reversibly-terminated nucleotide at its 3′ end such that the nucleotide molecule of the transient complex is not incorporated; and (ii) detecting a presence of the nucleotide molecule in the complex to identify a complementary nucleotide in the template nucleic acid molecule.
Owner:10X GENOMICS INC

Modified aptamer and application thereof

The invention provides a modified nucleic acid aptamer and application thereof. On the first aspect, the invention provides a modified nucleic acid aptamer, the nucleic acid aptamer is a nucleic acid aptamer Sgc8, and the nucleotide sequence of the nucleic acid aptamer Sgc8 is SEQ ID NO: 1; one end of the nucleic acid aptamer is extended through a polynucleotide fragment, and fluorescent molecular modification is carried out on the extended tail end of the polynucleotide fragment; the nucleotide sequence of the polynucleotide fragment is TTTTT. According to the invention, the base sequence with a certain length is added between the fluorescent molecule and the aptamer, so that the interference of the fluorescent molecule on an aptamer recognition structural domain can be effectively avoided, and the recognition and imaging efficiency is improved.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Deaminase, fusion protein, nucleic acid, pharmaceutical composition and use thereof

PCT designated stage expiredWO2025119295A1HydrolasesDepsipeptidesBase JPharmaceutical drug
A deaminase, a fusion protein and the use thereof. The deaminase contains an amino acid sequence having at least 50% sequence identity to any one of SEQ ID NOs: 1-6, 39-164 and 297-312, and the deaminase can deaminize at least one nucleotide in a target polynucleotide. The deaminase can be fused with a nucleic acid-binding polypeptide to obtain various base editors for the sequence-specific base conversion of the target polynucleotide. The performance of the editors can be further improved by means of fusing one or two UGIs, fusing a Gam protein and other strategies.
Owner:GUANGZHOU REFORGENE MEDICINE CO LTD

Anti-cmet antibodies

The present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to human cMET. The disclosure also provides polynucleotides encoding the antibodies or antigen binding fragments thereof, vectors comprising the polynucleotides, host cells comprising the vectors, methods of generating the antibodies, and compositions comprising the antibodies.
Owner:BEIGENE (SHANGHAI) CO LTD

Ketoalkyd reductoisomerase variant and method for producing L-valine using same

The present application relates to ketol reductoisomerase variants, polynucleotides encoding the variants of the present disclosure, L-valine-producing microorganisms comprising the ketol reductoisomerase variants of the present disclosure or the polynucleotides encoding the variants, and methods of producing L-valine using the microorganisms of the present disclosure.
Owner:CJ CHEILJEDANG CORP

Methods, systems, compositions and kits for target detection

PCT designated stage expiredWO2025145004A1Microbiological testing/measurementMultiplexAssay
Provided herein are methods, systems, compositions, and kits for detecting and decoding an encoded assay. The present disclosure provides low cost, multiplexed and automatable assays by hypercoding, a scalable technology for detection and quantitation of multi-omics targets. Hypercoding, or coding, utilizes signals from fluorescent hybridization with an error-corrected code to enable accurate detection and high-plexity targets of interest from samples. The present disclosure provides encoded assays for multiplex target detection from a sample suitable for detection by hybridization. Detection polynucleotide complexes, or detection oligonucleotides and anchor oligonucleotides, of the present disclosure are utilized in the detection and decoding of the hypercodes to produce optical signals capable of being decoded by a soft decision decoding algorithm for determining the presence of a target of interest, or multiple targets of interest, in a sample.
Owner:PLENO INC

Methods and compositions for improving plant traits

Disclosed herein are methods of increasing nitrogen fixation in a non-leguminous plant. The methods can comprise exposing the plant to a plurality of bacteria. Each member of the plurality comprises one or more genetic variations introduced into one or more genes or non-coding polynucleotides of the bacteria's nitrogen fixation or assimilation genetic regulatory network, such that the bacteria are capable of fixing atmospheric nitrogen in the presence of exogenous nitrogen. The bacteria are not intergeneric microorganisms. Additionally, the bacteria, in planta, produce 1% or more of the fixed nitrogen in the plant.
Owner:PIVOT BIO INC

Circular RNA compositions

Provided herein are circular RNA constructs comprising an IRES, and at least one expression sequence encoding binding molecule, compositions thereof, and methods of treating autoimmune disease. In particular, circular RNA comprising an IRES and a CD19 binder or a BCMA binder are provided, optionally formulated with a delivery vehicle. Precursor polynucleotides comprising an IRES, and at least one expression sequence encoding a CAR construct are also described herein.
Owner:ORNA THERAPEUTICS INC